BLFS

SEC source: 0001437749-23-000820 · rdgdoc.xml · derivative · entry 2

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,885

Underlying: Common Stock · 11,885 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

SEC source: 0001437749-23-000820 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,265

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

SEC source: 0001437749-23-000819 · rdgdoc.xml · derivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,978

Underlying: Common Stock · 16,978 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

SEC source: 0001437749-23-000819 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,789

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

SEC source: 0001437749-23-000818 · rdgdoc.xml · derivative · entry 2

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,733

Underlying: Common Stock · 12,733 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

SEC source: 0001437749-23-000818 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,233

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

SEC source: 0001437749-23-000817 · rdgdoc.xml · derivative · entry 2

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,939

Underlying: Common Stock · 20,939 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

SEC source: 0001437749-23-000817 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,765

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

SEC source: 0001437749-23-000816 · rdgdoc.xml · derivative · entry 2

Phillips Geraint · CIK 0001960665 · SVP, Global Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,222

Underlying: Common Stock · 21,222 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

SEC source: 0001437749-23-000816 · rdgdoc.xml · nonDerivative · entry 1

Phillips Geraint · CIK 0001960665 · SVP, Global Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,584

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

SEC source: 0001437749-23-000815 · rdgdoc.xml · derivative · entry 2

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,295

Underlying: Common Stock · 34,295 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

SEC source: 0001437749-23-000815 · rdgdoc.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,946

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

SEC source: 0001437749-23-000814 · rdgdoc.xml · derivative · entry 2

Rice Michael · CIK 0001389512 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,038

Underlying: Common Stock · 99,038 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

SEC source: 0001437749-23-000814 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 456,613

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

SEC source: 0001437749-23-001264 · rdgdoc.xml · nonDerivative · entry 1

Ellingson Rachel · CIK 0001557271 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,828

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date.

SEC source: 0001437749-23-001268 · rdgdoc.xml · nonDerivative · entry 1

DuRoss Amy · CIK 0001854968 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,344

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date.

SEC source: 0001437749-23-001267 · rdgdoc.xml · nonDerivative · entry 1

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,636

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date.

SEC source: 0001437749-23-001266 · rdgdoc.xml · nonDerivative · entry 1

MOORE TIMOTHY L. · CIK 0001669207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,776

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date.

SEC source: 0001437749-23-001265 · rdgdoc.xml · nonDerivative · entry 1

GOSWAMI JOYDEEP · CIK 0001533115 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,847

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date.

SEC source: 0001437749-22-029958 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,811

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-029957 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 357,575

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-029956 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,380

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-029955 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,826

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-029734 · rdgdoc.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,651

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-028232 · rdgdoc.xml · nonDerivative · entry 4

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,314

F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.83, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-028235 · rdgdoc.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,179

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-028236 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,538

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-028234 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,473

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-028233 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,416

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-028232 · rdgdoc.xml · nonDerivative · entry 3

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,219

F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.13 to $20.25, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-028232 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,719

F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.64, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-028232 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,119

F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.29 to $21.29, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-028058 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,719

F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.52 to $21.88, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-028121 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359,404

F1 · kind: This transaction represents a charitable donation to a charity. No value was received for the gifted shares.

SEC source: 0001437749-22-028059 · rdgdoc.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,231

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-028058 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,219

F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $21.81, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-027791 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,719

F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.08 to $22.22, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-027683 · rdgdoc.xml · nonDerivative · entry 1

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,449

SEC source: 0001437749-22-027791 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,219

F1 · kind: As previously disclosed, the reporting person is retiring from his position as President and Chief Operating Officer effective January 3, 2023. The reporting person is selling these shares for retirement planning.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.15 to $23.29, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-027684 · rdgdoc.xml · nonDerivative · entry 1

DuRoss Amy · CIK 0001854968 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,157

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.31 to $24.39, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-027484 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,719

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.15 to $24.94, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-027484 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · COO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,719

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.09 to $24.07, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-22-027400 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 362,154

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-027399 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,974

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-027398 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,500

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-027397 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,723

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-027396 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,881

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-027395 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,091

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-025240 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,540

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-22-025239 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,129

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.